Abstract 951P
Background
Preventing post-operative recurrence and metastasis has become a critical factor in determining the success of hepatectomy for HCC patients (pts). However, the optimal treatment strategy for adjuvant therapy is still under debate. The aim of this study was to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anlotinib and TQB2450 (PD-L1 monoclonal antibody) as adjuvant therapy for pts with HCC at high risk of recurrence after hepatectomy.
Methods
Pts diagnosed as HCC with one or more of the high risk factors after hepatectomy were eligible. Eligible pts received FOLFOX-HAIC (1 cycle) within 1 months after hepatectomy, and on the 2nd day after HAIC, anlotinib (10mg, 4 cycles or 8 cycles) and TQB2450 (1200mg, 4 cycles) were given. The primary endpoint was disease free survival (DFS). Secondary endpoints included overall survival (OS), time to recurrence (TTR) and safety.
Results
At April 18 2023, 72 pts were enrolled and 68 were available to be analyzed. Among them, 34 pts have completed treatment, 26 pts were still on treatment, 8 pts discontinued treatmentearly due to adverse events (AE). 70.6% with liver cirrhosis, 67.7% with MVI, 33.8% with preoperative intrahepatic lesions≥8cm, 7.4% with≥3tumor lesions, 2.9% with tumor thrombus, and 2.9% with preoperative rupture of the tumor or invasion of adjacent organs. At median follow-up of 6.0 (range 0.9-15.1) months, 1 pts relapsed (DFS was 10.87 months).1-year DFS rate was 85.7%, and the longest DFS was over 16.92 months in all pts. The median DFS and OS were not available. Safety profile indicated that 67 pts (98.5%) experienced treatment-related adverse events (TRAEs), and common grade 3 TRAEs included hypertension (8.8%), neutropenia (7.4%) and thrombocytopenia (5.9%).
Conclusions
HAIC combined with anlotinib and TQB2450 as adjuvant therapy for pts with HCC at high risk of recurrence after primary hepatectomy exhibits promising prognosis and tolerable safety profile, and further follow-up is needed for this study to obtain mature data.
Clinical trial identification
NCT05311319.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chia-Tai Tianqing Pharmaceutical Group Co Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18